About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 69067 record(s)
Req # A-2023-000268
Module 5.2 (Tabular Listing of all Clinical Studies) for pms-Iron Sucrose that received a Notice of Compliance on 30 July 2020. Drug Identification Number (DIN) 02502917.Organization: Health Canada
February 2024
Req # A-2023-000395
The clinical trails for the premarket approval of the Selective Serotonin Reuptake Inhibitors (SNRI) antidepressant Effexor. The table of contents for all of those 12 paper volumes.Organization: Health Canada
February 2024
Req # A-2023-000426
PERIODIC SAFETY UPDATE REPORT #3 for COVID-19 VACCINE (nucleoside modified) (BNT162b2) to the European Medical Agency (EMA) on Aug 18, 2022 which covered the period from December 19, 2021 through June 18, 2022. Health Canada's and the Public…Organization: Health Canada
February 2024
Req # A-2023-000432
Correspondence to and from the minister of Mental Health and Addictions concerning possible changes to the guidance on alcohol consumption in the time frame: January 1, 2022 to June 30 and July 1, 2022 to February 28, 2023.Organization: Health Canada
February 2024
Req # A-2023-000504
Acknowledgement letters from Health Canada to potential sponsor(s) regarding New Drug Submissions (NDS) currently under review for NURTEC ODT, including proposed indication.Organization: Health Canada
February 2024
Req # A-2023-000598
All notes made by the Health Canada employees who reviewed the Novavax Nuvaxovid COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.Organization: Health Canada
February 2024
Req # A-2023-000615
Information related to Tiotropium bromide monohydrate that Health Canada is currently reviewing. The product name and/or Drug Identification Number (DIN) of the reference product for which the Abbreviated New Drug Submission (ANDS) submission for…Organization: Health Canada
February 2024
Req # A-2023-000716
All records pertaining to the medical relocations of Canadians facilitated or financed by the federal government from 2018 to August 20, 2024.Organization: Health Canada
February 2024
Req # A-2023-000738
All documents submitted in the medical device license application, resulting in Rapid Self Test's Medical Device License (MDL) #102099.Organization: Health Canada
February 2024
Req # A-2023-000820
With respect to the Abbreviated New Drug Submission (ANDS) for liraglutide accepted into review on August 2017, copies of any Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W), a NON-Withdrawal (NON-W) or sponsor…Organization: Health Canada
February 2024